Julia Kravchenko1, Mark Berry2, Konstantin Arbeev3, H Kim Lyerly4, Anatoly Yashin3, Igor Akushevich3. 1. Department of Surgery, Duke University Medical Center, Duke University, Durham, NC, USA. Electronic address: julia.krauchanka@duke.edu. 2. Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, USA. 3. Center for Population Health and Aging, Duke University, Durham, NC, USA. 4. Department of Surgery, Duke University Medical Center, Duke University, Durham, NC, USA; Department of Pathology, Duke University Medical Center, Duke University, Durham, NC, USA.
Abstract
OBJECTIVES: To evaluate the role of cardiovascular disease (CVD) comorbidity in survival of patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: The impact of seven CVDs (at the time of NSCLC diagnosis and during subsequent follow-up) on overall survival was studied for NSCLC patients aged 65+ years using the Surveillance, Epidemiology, and End Results data linked to the U.S. Medicare data, cancer stage- and treatment-specific. Cox regression was applied to evaluate death hazard ratios of CVDs in univariable and multivariable analyses (controlling by age, TNM statuses, and 78 non-CVD comorbidities) and to investigate the effects of 128 different combinations of CVDs on patients' survival. RESULTS: Overall, 95,167 patients with stage I (n=29,836, 31.4%), II (n=5133, 5.4%), IIIA (n=11,884, 12.5%), IIIB (n=18,020, 18.9%), and IV (n=30,294, 31.8%) NSCLC were selected. Most CVDs increased the risk of death for stages I-IIIB patients, but did not significantly impact survival of stage IV patients. The worse survival of patients was associated with comorbid heart failure, myocardial infarction, and cardiac arrhythmias that occurred during a period of follow-up: HRs up to 1.85 (p<0.001), 1.96 (p<0.05), and 1.67 (p<0.001), respectively, varying by stage and treatment. The presence of hyperlipidemia at baseline (HR down to 0.71, p<0.05) was associated with better prognosis. Having multiple co-existing CVDs significantly increased mortality for all treatments, especially for stages I and II patients treated with surgery (HRs up to 2.89, p<0.05) and stages I-IIIB patients treated with chemotherapy (HRs up to 2.59, p<0.001) and chemotherapy and radiotherapy (HRs up to 2.20, p<0.001). CONCLUSION: CVDs impact the survival of NSCLC patients, particularly when multiple co-existing CVDs are present; the impacts vary by stage and treatment. This data should be considered in improving cancer treatment selection process for such potentially challenging patients as the elderly NSCLC patients with CVD comorbidities.
OBJECTIVES: To evaluate the role of cardiovascular disease (CVD) comorbidity in survival of patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: The impact of seven CVDs (at the time of NSCLC diagnosis and during subsequent follow-up) on overall survival was studied for NSCLCpatients aged 65+ years using the Surveillance, Epidemiology, and End Results data linked to the U.S. Medicare data, cancer stage- and treatment-specific. Cox regression was applied to evaluate death hazard ratios of CVDs in univariable and multivariable analyses (controlling by age, TNM statuses, and 78 non-CVD comorbidities) and to investigate the effects of 128 different combinations of CVDs on patients' survival. RESULTS: Overall, 95,167 patients with stage I (n=29,836, 31.4%), II (n=5133, 5.4%), IIIA (n=11,884, 12.5%), IIIB (n=18,020, 18.9%), and IV (n=30,294, 31.8%) NSCLC were selected. Most CVDs increased the risk of death for stages I-IIIB patients, but did not significantly impact survival of stage IV patients. The worse survival of patients was associated with comorbid heart failure, myocardial infarction, and cardiac arrhythmias that occurred during a period of follow-up: HRs up to 1.85 (p<0.001), 1.96 (p<0.05), and 1.67 (p<0.001), respectively, varying by stage and treatment. The presence of hyperlipidemia at baseline (HR down to 0.71, p<0.05) was associated with better prognosis. Having multiple co-existing CVDs significantly increased mortality for all treatments, especially for stages I and IIpatients treated with surgery (HRs up to 2.89, p<0.05) and stages I-IIIB patients treated with chemotherapy (HRs up to 2.59, p<0.001) and chemotherapy and radiotherapy (HRs up to 2.20, p<0.001). CONCLUSION: CVDs impact the survival of NSCLCpatients, particularly when multiple co-existing CVDs are present; the impacts vary by stage and treatment. This data should be considered in improving cancer treatment selection process for such potentially challenging patients as the elderly NSCLCpatients with CVD comorbidities.
Authors: Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: David S Ettinger; Wallace Akerley; Gerold Bepler; Matthew G Blum; Andrew Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Apar Kishor P Ganti; Ramaswamy Govindan; Frederic W Grannis; Thierry Jahan; Mohammad Jahanzeb; David H Johnson; Anne Kessinger; Ritsuko Komaki; Feng-Ming Kong; Mark G Kris; Lee M Krug; Quynh-Thu Le; Inga T Lennes; Renato Martins; Janis O'Malley; Raymond U Osarogiagbon; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; George R Simon; Scott J Swanson; Douglas E Wood; Stephen C Yang Journal: J Natl Compr Canc Netw Date: 2010-07 Impact factor: 11.908
Authors: Richard J Battafarano; Jay F Piccirillo; Bryan F Meyers; Han-Shui Hsu; Tracey J Guthrie; Joel D Cooper; G Alexander Patterson Journal: J Thorac Cardiovasc Surg Date: 2002-02 Impact factor: 5.209
Authors: Eric E Roselli; Sudish C Murthy; Thomas W Rice; Penny L Houghtaling; Christopher D Pierce; Daniel P Karchmer; Eugene H Blackstone Journal: J Thorac Cardiovasc Surg Date: 2005-08 Impact factor: 5.209
Authors: Miguel Cainzos-Achirica; Philip A Di Carlo; Catherine E Handy; Renato Quispe; Gerard Roura; Xavier Pinto; Roger S Blumenthal; Josep Comin-Colet; Xavier Corbella; Michael J Blaha Journal: Curr Cardiol Rep Date: 2018-07-10 Impact factor: 2.931
Authors: Donald R Sullivan; Karen B Eden; Nathan F Dieckmann; Sara E Golden; Kelly C Vranas; Shannon M Nugent; Christopher G Slatore Journal: Lung Cancer Date: 2019-03-09 Impact factor: 5.705
Authors: Clara Faubry; Maxime Faure; Anne-Claire Toublanc; Rémi Veillon; Anne-Iris Lemaître; Charlotte Vergnenègre; Hubert Cochet; Sadia Khan; Chantal Raherison; Pierre Dos Santos; Maeva Zysman Journal: Front Cardiovasc Med Date: 2022-06-06
Authors: Nam P Nguyen; Juan Godinez; Wei Shen; Vincent Vinh-Hung; Helena Gorobets; Juliette Thariat; Fred Ampil; Jacqueline Vock; Ulf Karlsson; Alexander Chi Journal: Medicine (Baltimore) Date: 2016-10 Impact factor: 1.889